INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Innovaderm is proudly supporting AID as a Premier sponsor!

Indero

Indero

Team of Experts

Author picture

Innovaderm is delighted to announce its continued sponsorship of Advancing Innovation in Dermatology (AID) for another year!

As part of our 2023 sponsorship, we proudly supported 2 of the recent AID webinars:

PUTTING THE BRAKES ON AUTOIMMUNITY: CHECKPOINT AGONISTS IN DERMATOLOGY

    • featuring contributions from EQRx, Eli Lilly, AnaptysBio, as well as University of Zurich and Yale School of Medicine.

 

THE SCIENCE BEHIND INNOVATIONS IN TOPICAL GENERIC DRUG ASSESSMENT: OPPORTUNITIES AND CHALLENGES

    with the participation of the Food and Drug Administration (FDA).

 

For 2024, Innovaderm has elevated its commitment by taking he stage at the upcoming Dermatology Summit in San Francisco on January 7th, and also becoming a Premier Sponsor. Dr. Jasmina Jankicevic, Innovaderm’s Chief Medical Officer, will be presenting on: “Clinical Development Strategy that Patients Need and Investors Want”.

Learn more and listen to Dr. Jankicevic sharing further insights here!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >